{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:13:42Z","timestamp":1788200022551,"version":"build-2803163510"},"reference-count":75,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Non-small-cell lung cancer (NSCLC) remains the leading cause of lung cancer\u2013related mortality, largely driven by aberrant activation of the epidermal growth factor receptor (EGFR). Despite the clinical success of EGFR tyrosine kinase inhibitors (TKIs), intrinsic and acquired resistance, coupled with safety concerns, highlight the need for novel, safer inhibitors. Natural products represent an underexplored source of structurally diverse bioactive compounds with favorable biocompatibility. In this study, a comprehensive in silico approach is used to evaluate phytochemicals from\n                    <jats:italic>Adenium obesum<\/jats:italic>\n                    as potential candidate EGFR-targeting compound. Initially, sixteen phytochemicals were first assessed for predicted antineoplastic activity using PASS. High-scoring molecules were docked against the EGFR kinase domain (PDB ID: 1M17), besides performed detailed protein\u2013ligand interaction analysis, drug-likeness and ADMET profiling, toxicity prediction and 100-ns molecular dynamics (MD) simulations. PASS-based bioactivity prediction revealed strong anticancer potential among the sixteen screened compounds, with consistently high antineoplastic and antiproliferative activity probabilities (Pa\u2009&gt;\u20090.79) and low inactivity scores, supporting their selection for subsequent docking, ADMET, and molecular dynamics analyses. Next, several phytochemicals exhibited strong docking affinities, with Cardenolide achieving the highest binding score (\u20139.9 kcal\/mol) and forming stable interactions with key catalytic residues. A 100-ns MD simulation confirmed the structural stability, persistent binding, and dynamic integrity of the EGFR\u2013Cardenolide complex under physiological conditions. Importantly, interaction mapping revealed that Cardenolide engages conserved and functionally critical regions of the EGFR kinase domain associated with catalytic activity and structural stability, supporting its mechanistic relevance as an ATP-competitive scaffold. Additionally, predicted pharmacokinetic and toxicity profiles further supported Cardenolide\u2019s suitability as a drug-like candidate. Collectively, these results identify Cardenolide as a computationally prioritized candidate with favorable predicted EGFR-binding characteristics, structural stability, and physicochemical and toxicity profiles. However, as the present study is based entirely on computational analyses, these findings should be considered hypothesis-generating and do not establish EGFR inhibitory activity or therapeutic efficacy. Experimental validation, including biochemical kinase inhibition and cellular assays, is therefore required to determine the actual EGFR inhibitory potential and anticancer activity of Cardenolide. Nevertheless, the findings provide a rational basis for prioritizing Cardenolide for further experimental investigation and illustrate the potential of Adenium obesum phytochemicals as a source of candidate EGFR-targeting compounds for future NSCLC drug discovery.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0357096","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:23:04Z","timestamp":1788196984000},"page":"e0357096","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computational identification and evaluation of Adenium obesum phytochemicals as potential EGFR inhibitors for targeted therapy against non-small-cell lung cancer"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3443-0180","authenticated-orcid":true,"given":"Md. Naziur","family":"Rahman","sequence":"first","affiliation":[{"name":"IUBAT\u2014International University of Business Agriculture and Technology","place":["Dhaka, Bangladesh"],"department":["College of Agricultural Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu Yousuf","family":"Hossin","sequence":"additional","affiliation":[{"name":"IUBAT\u2014International University of Business Agriculture and Technology","place":["Dhaka, Bangladesh"],"department":["College of Agricultural Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5634-5908","authenticated-orcid":true,"given":"Shahriar Mannan Imon","family":"Talukder","sequence":"additional","affiliation":[{"name":"IUBAT\u2014International University of Business Agriculture and Technology","place":["Dhaka, Bangladesh"],"department":["College of Agricultural Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mt. Sumaiya","family":"Siddika","sequence":"additional","affiliation":[{"name":"Barind Medical College & Hospital","place":["Rajshahi, Bangladesh"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md.","family":"Harun-Ur-Rashid","sequence":"additional","affiliation":[{"name":"Sher-e-Bangla Agricultural University","place":["Dhaka, Bangladesh"],"department":["Department of Genetics and Plant Breeding, Faculty of Agriculture"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahanaz","family":"Parveen","sequence":"additional","affiliation":[{"name":"Sher-e-Bangla Agricultural University","place":["Dhaka, Bangladesh"],"department":["Department of Genetics and Plant Breeding, Faculty of Agriculture"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Ridwanul","family":"Islam","sequence":"additional","affiliation":[{"name":"Sher-e-Bangla Agricultural University","place":["Dhaka, Bangladesh"],"department":["Department of Genetics and Plant Breeding, Faculty of Agriculture"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Yeamin","family":"Hossain","sequence":"additional","affiliation":[{"name":"Sher-e-Bangla Agricultural University","place":["Dhaka, Bangladesh"],"department":["Department of Genetics and Plant Breeding, Faculty of Agriculture"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7019-4467","authenticated-orcid":true,"given":"Mahfuj","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Sher-e-Bangla Agricultural University","place":["Dhaka, Bangladesh"],"department":["Department of Genetics and Plant Breeding, Faculty of Agriculture"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brototi Chakraborty","family":"Dyuti","sequence":"additional","affiliation":[{"name":"IUBAT\u2014International University of Business Agriculture and Technology","place":["Dhaka, Bangladesh"],"department":["College of Agricultural Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarin","family":"Tabassum","sequence":"additional","affiliation":[{"name":"IUBAT\u2014International University of Business Agriculture and Technology","place":["Dhaka, Bangladesh"],"department":["College of Agricultural Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-6166","authenticated-orcid":true,"given":"Ajoy","family":"Kumer","sequence":"additional","affiliation":[{"name":"Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences","place":["Chennai, India"],"department":["Department of General Medicine"]},{"name":"IUBAT\u2014International University of Business Agriculture and Technology","place":["Dhaka, Bangladesh"],"department":["Department of Chemistry, College of Arts and Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"9","key":"pone.0357096.ref001","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"A Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"pone.0357096.ref002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"pone.0357096.ref003","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.3390\/biomedicines11071982","article-title":"Small Cell Lung Carcinoma: Current Diagnosis, Biomarkers, and Treatment Options with Future Perspectives","volume":"11","author":"K Krpina","year":"2023","journal-title":"Biomedicines"},{"key":"pone.0357096.ref004","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/B978-0-443-33849-6.00015-5","article-title":"Lung cancer: Advances in diagnostic research","volume-title":"Diagnostic Landscape in Cancer Research","author":"R Pokale","year":"2025"},{"issue":"3","key":"pone.0357096.ref005","doi-asserted-by":"crossref","first-page":"975","DOI":"10.21037\/tlcr-24-979","article-title":"Recent advancements in lung cancer research: a narrative review","volume":"14","author":"FH Tang","year":"2025","journal-title":"Transl Lung Cancer Res"},{"issue":"19","key":"pone.0357096.ref006","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.3390\/cancers14194765","article-title":"The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives","volume":"14","author":"V Cognigni","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"pone.0357096.ref007","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/ijms22020612","article-title":"Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer","volume":"22","author":"SS Fois","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"pone.0357096.ref008","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/labinvest.2013.147","article-title":"Epidermal growth factor receptor mutations in lung adenocarcinoma","volume":"94","author":"MD Siegelin","year":"2014","journal-title":"Lab Invest"},{"issue":"6","key":"pone.0357096.ref009","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12032-025-02755-9","article-title":"Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs","volume":"42","author":"K Kannan","year":"2025","journal-title":"Med Oncol"},{"issue":"6","key":"pone.0357096.ref010","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3390\/pharmaceutics15061604","article-title":"The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies","volume":"15","author":"C Laface","year":"2023","journal-title":"Pharmaceutics"},{"issue":"43","key":"pone.0357096.ref011","doi-asserted-by":"crossref","first-page":"75712","DOI":"10.18632\/oncotarget.20095","article-title":"EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer","volume":"8","author":"X Nan","year":"2017","journal-title":"Oncotarget"},{"key":"pone.0357096.ref012","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.2147\/OTT.S198945","article-title":"Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer","volume":"12","author":"S Wang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"pone.0357096.ref013","first-page":"109","article-title":"Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy","volume":"8","author":"M Santarpia","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"issue":"19","key":"pone.0357096.ref014","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.3390\/cancers13194926","article-title":"Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring","volume":"13","author":"D Reita","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0357096.ref015","doi-asserted-by":"crossref","first-page":"2574526","DOI":"10.1080\/07853890.2025.2574526","article-title":"Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer","volume":"57","author":"J Wang","year":"2025","journal-title":"Ann Med"},{"issue":"1","key":"pone.0357096.ref016","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/ddc3010011","article-title":"Plant-derived natural products: A source for drug discovery and development","volume":"3","author":"N Chaachouay","year":"2024","journal-title":"Drugs Drug Candidates"},{"issue":"1","key":"pone.0357096.ref017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/biomedicines12010201","article-title":"Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies","volume":"12","author":"P Chunarkar-Patil","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"pone.0357096.ref018","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/biomedicines12010201","article-title":"Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies","volume":"12","author":"P Chunarkar-Patil","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"pone.0357096.ref019","doi-asserted-by":"crossref","first-page":"100396","DOI":"10.1016\/j.phyplu.2022.100396","article-title":"Anticancer properties and mechanisms of botanical derivatives","volume":"3","author":"S Banerjee","year":"2023","journal-title":"Phytomedicine Plus"},{"issue":"4","key":"pone.0357096.ref020","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/molecules26041109","article-title":"Plant-derived anticancer compounds as new perspectives in drug discovery and alternative therapy","volume":"26","author":"CA Dehelean","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"pone.0357096.ref021","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bjbas.2018.06.008","article-title":"A review on Adenium obesum: A potential endemic medicinal plant in Oman","volume":"7","author":"MdA Hossain","year":"2018","journal-title":"Beni-Suef University Journal of Basic and Applied Sciences"},{"key":"pone.0357096.ref022","unstructured":"Tiwari DS, Talreja S. Exploring the mysterious adenium obesum: its botanical appeal, ecological significance, cultivation insights, and potential medicinal applications. 2023."},{"key":"pone.0357096.ref023","unstructured":"Vikhe S, Gunjal G, Ahire M. Effects, pharmacological actions, phytochemical components and therapeutic applications of Adenium obesum. 2024;13(5)."},{"issue":"3","key":"pone.0357096.ref024","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jtcme.2016.08.003","article-title":"Isolation and characterization of antimicrobial compound from the stem-bark of the traditionally used medicinal plant Adenium obesum","volume":"7","author":"MS Akhtar","year":"2016","journal-title":"J Tradit Complement Med"},{"key":"pone.0357096.ref025","doi-asserted-by":"crossref","first-page":"847534","DOI":"10.3389\/fphar.2022.847534","article-title":"In Vitro Evaluation of Antioxidant, Anticancer, and Anti-Inflammatory Activities of Ethanolic Leaf Extract of Adenium obesum","volume":"13","author":"A Alshehri","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0357096.ref026","doi-asserted-by":"crossref","first-page":"116423","DOI":"10.1016\/j.biopha.2024.116423","article-title":"Recent advances in application of computer-aided drug design in anti-COVID-19 virials drug discovery","volume":"173","author":"W Yang","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"pone.0357096.ref027","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/pharmaceutics16101328","article-title":"Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine","volume":"16","author":"DR Serrano","year":"2024","journal-title":"Pharmaceutics"},{"issue":"4","key":"pone.0357096.ref028","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.18632\/oncotarget.6755","article-title":"The drug target genes show higher evolutionary conservation than non-target genes","volume":"7","author":"W Lv","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"pone.0357096.ref029","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae514","article-title":"Mut-Map: Comprehensive Computational Pipeline for Structural Mapping and Analysis of Cancer-Associated Mutations","volume":"25","author":"AF Alsulami","year":"2024","journal-title":"Brief Bioinform"},{"key":"pone.0357096.ref030","doi-asserted-by":"crossref","first-page":"101998","DOI":"10.1016\/j.toxrep.2025.101998","article-title":"Pharmacological potential of bioactive compounds in Catharanthus roseus extract: A comprehensive review","volume":"14","author":"KC Mendonce","year":"2025","journal-title":"Toxicol Rep"},{"key":"pone.0357096.ref031","article-title":"Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective","author":"N Guex","year":"2009","journal-title":"Electrophoresis"},{"issue":"1","key":"pone.0357096.ref032","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1038\/s41598-018-22631-z","article-title":"IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics","volume":"8","author":"K Mohanraj","year":"2018","journal-title":"Scientific Reports"},{"issue":"11","key":"pone.0357096.ref033","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2025.08.006","article-title":"The Expanding Landscape of Next-Generation EGFR Tyrosine Kinase Inhibitors: Have We Reached Capacity?","volume":"20","author":"K Sankar","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"7","key":"pone.0357096.ref034","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.21873\/anticanres.13544","article-title":"Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib\/Erlotinib?","volume":"39","author":"M Tamiya","year":"2019","journal-title":"Anticancer Res"},{"issue":"2","key":"pone.0357096.ref035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cpt.2024.06.004","article-title":"A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer","volume":"3","author":"J Yin","year":"2025","journal-title":"Cancer Pathog Ther"},{"key":"pone.0357096.ref036","article-title":"PubChem 2023 update","volume":"51","author":"S Kim","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"pone.0357096.ref037","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.insi.2025.100080","article-title":"Computational study for the identification of phytochemical from Acacia hydaspica as potent inhibitor for addressing KRAS-related non-small cell lung cancer: Perspectives on ligand-based drug discovery","volume":"1","author":"MN Rabbi","year":"2025","journal-title":"In Silico Research in Biomedicine"},{"issue":"1","key":"pone.0357096.ref038","doi-asserted-by":"crossref","first-page":"13398","DOI":"10.1038\/s41598-023-40160-2","article-title":"Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management","volume":"13","author":"PC Agu","year":"2023","journal-title":"Sci Rep"},{"key":"pone.0357096.ref039","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","article-title":"Small-molecule library screening by docking with PyRx","volume":"1263","author":"S Dallakyan","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"12","key":"pone.0357096.ref040","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3390\/ph18121777","article-title":"Docking in the Dark: Insights into Protein\u2013Protein and Protein\u2013Ligand Blind Docking","volume":"18","author":"MS Roomi","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"2","key":"pone.0357096.ref041","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"KS Gajiwala","year":"2013","journal-title":"Structure"},{"key":"pone.0357096.ref042","doi-asserted-by":"crossref","unstructured":"Kawauchi H. Crystal structure of EGFR(L858R\/T790M\/C797S) in complex with osimertinib: 6lud. 2020. https:\/\/doi.org\/10.2210\/pdb6lud\/pdb","DOI":"10.2210\/pdb6lud\/pdb"},{"issue":"6","key":"pone.0357096.ref043","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1021\/ci6004299","article-title":"Validation studies of the site-directed docking program LibDock","volume":"47","author":"SN Rao","year":"2007","journal-title":"J Chem Inf Model"},{"key":"pone.0357096.ref044","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-803620-4.00003-7","article-title":"ADME in Drug Discovery","volume-title":"A Comprehensive Guide to Toxicology in Nonclinical Drug Development","author":"J Vrbanac","year":"2017"},{"issue":"5","key":"pone.0357096.ref045","doi-asserted-by":"crossref","first-page":"052502","DOI":"10.1063\/5.0213317","article-title":"Quantum chemical package Jaguar: A survey of recent developments and unique features","volume":"161","author":"Y Cao","year":"2024","journal-title":"J Chem Phys"},{"issue":"2","key":"pone.0357096.ref046","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1021\/ct700248k","article-title":"Performance of B3LYP Density Functional Methods for a Large Set of Organic Molecules","volume":"4","author":"J Tirado-Rives","year":"2008","journal-title":"J Chem Theory Comput"},{"key":"pone.0357096.ref047","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw408","article-title":"ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules","volume":"44","author":"H Ashkenazy","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"pone.0357096.ref048","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"EF Pettersen","year":"2021","journal-title":"Protein Sci"},{"key":"pone.0357096.ref049","article-title":"GEPIA3: Enhanced drug sensitivity and interaction network analysis for cancer research","volume":"53","author":"Y-J Kang","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"269","key":"pone.0357096.ref050","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"J Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"6","key":"pone.0357096.ref051","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","article-title":"An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor","volume":"125","author":"X Zhang","year":"2006","journal-title":"Cell"},{"key":"pone.0357096.ref052","doi-asserted-by":"crossref","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update","volume":"200","author":"Jr Roskoski R","year":"2024","journal-title":"Pharmacol Res"},{"issue":"1","key":"pone.0357096.ref053","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/cb500870a","article-title":"Targeting conformational plasticity of protein kinases","volume":"10","author":"M Tong","year":"2015","journal-title":"ACS Chem Biol"},{"issue":"3","key":"pone.0357096.ref054","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/molecules27030819","article-title":"Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors","volume":"27","author":"T Amelia","year":"2022","journal-title":"Molecules"},{"issue":"11","key":"pone.0357096.ref055","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/cryst15110935","article-title":"Synthesis, EGFR inhibitors, Crystal Structure, and Molecular Docking of 2-Amino-6-methoxy-4-(2-bromophenyl)-4H-benzo [h]chromene-3-carbonitrile","volume":"15","author":"A-AM Al-Dies","year":"2025","journal-title":"Crystals"},{"issue":"1","key":"pone.0357096.ref056","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12860-019-0218-z","article-title":"Using parallelized incremental meta-docking can solve the conformational sampling issue when docking large ligands to proteins","volume":"20","author":"D Devaurs","year":"2019","journal-title":"BMC Mol Cell Biol"},{"issue":"1","key":"pone.0357096.ref057","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/pr9010071","article-title":"Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development","volume":"9","author":"OMH Salo-Ahen","year":"2020","journal-title":"Processes"},{"key":"pone.0357096.ref058","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-0716-3441-7_7","article-title":"Applications of Molecular Dynamics Simulations in Drug Discovery.","volume-title":"Computational Drug Discovery and Design","author":"S AlRawashdeh","year":"2024"},{"issue":"11","key":"pone.0357096.ref059","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202300115","article-title":"Absorption matters: A closer look at popular oral bioavailability rules for drug approvals","volume":"42","author":"A Caminero Gomes Soares","year":"2023","journal-title":"Mol Inform"},{"key":"pone.0357096.ref060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/9781394249190.ch6","article-title":"ADMET and physicochemical assessments in drug design.","volume-title":"Computational methods for rational drug design","author":"UA \u00c7evik","year":"2025","edition":"1"},{"key":"pone.0357096.ref061","volume-title":"Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization","author":"EH Kerns","year":"2008"},{"issue":"3","key":"pone.0357096.ref062","first-page":"251","article-title":"Modes of Action of Herbal Medicines and Plant Secondary Metabolites","volume":"2","author":"M Wink","year":"2015","journal-title":"Medicines (Basel)"},{"issue":"11","key":"pone.0357096.ref063","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nrd2682","article-title":"Novel therapeutic applications of cardiac glycosides","volume":"7","author":"I Prassas","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"pone.0357096.ref064","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/mi.8.1.8","article-title":"Cardiac glycosides as novel cancer therapeutic agents","volume":"8","author":"RA Newman","year":"2008","journal-title":"Mol Interv"},{"issue":"11","key":"pone.0357096.ref065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acscombsci.0c00082","article-title":"Prospects and Therapeutic Applications of Cardiac Glycosides in Cancer Remediation","volume":"22","author":"JI Ayogu","year":"2020","journal-title":"ACS Comb Sci"},{"issue":"9","key":"pone.0357096.ref066","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-14-0326","article-title":"Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations","volume":"4","author":"YY Janjigian","year":"2014","journal-title":"Cancer Discov"},{"key":"pone.0357096.ref067","doi-asserted-by":"crossref","first-page":"611657","DOI":"10.3389\/fphar.2021.611657","article-title":"The Cardenolide Glycoside Acovenoside A Interferes with Epidermal Growth Factor Receptor Trafficking in Non-Small Cell Lung Cancer Cells","volume":"12","author":"S Hafner","year":"2021","journal-title":"Front Pharmacol"},{"key":"pone.0357096.ref068","doi-asserted-by":"crossref","first-page":"1764550","DOI":"10.3389\/fphar.2026.1764550","article-title":"Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials","volume":"17","author":"AF Wali","year":"2026","journal-title":"Front Pharmacol"},{"issue":"12","key":"pone.0357096.ref069","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.3390\/molecules27123816","article-title":"Anti-Cancer Effects of Dietary Polyphenols via ROS-Mediated Pathway with Their Modulation of MicroRNAs","volume":"27","author":"Y Yoshioka","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"pone.0357096.ref070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40495-024-00379-7","article-title":"Curcumin and epigallocatechin-3-gallate: targeting receptor tyrosine kinases and their signaling pathways in cancer therapy","volume":"10","author":"N Ghobadi","year":"2024","journal-title":"Current Pharmacology Reports"},{"issue":"5","key":"pone.0357096.ref071","first-page":"1","article-title":"Use of curcumin with tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. A phase I prospective cohort trial","volume":"7","author":"P Brojde","year":"2021","journal-title":"J Altern Complement Integr Med"},{"issue":"6","key":"pone.0357096.ref072","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.18632\/aging.101250","article-title":"Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs","volume":"9","author":"JA McCubrey","year":"2017","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"pone.0357096.ref073","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/cimb48020172","article-title":"Plant-derived secondary metabolites modulating inflammation-driven pathways in hepatocellular carcinoma: preclinical insights","volume":"48","author":"SA Mendoza-Calder\u00f3n","year":"2026","journal-title":"Current Issues in Molecular Biology"},{"issue":"14","key":"pone.0357096.ref074","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.3390\/molecules31142469","article-title":"Natural Products in Cancer Research: Mechanistic Advances, Translational Challenges, and the Emerging Role of Chilean Biodiversity","volume":"31","author":"R Gonz\u00e1lez-Stegmaier","year":"2026","journal-title":"Molecules"},{"issue":"46","key":"pone.0357096.ref075","doi-asserted-by":"crossref","first-page":"76076","DOI":"10.18632\/oncotarget.12589","article-title":"Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer","volume":"7","author":"J Wang","year":"2016","journal-title":"Oncotarget"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:23:15Z","timestamp":1788196995000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357096"}},"subtitle":[],"editor":[{"given":"Lalit","family":"Samant","sequence":"first","affiliation":[{"name":"Bai Jerbai Wadia Hospital for Children","place":["INDIA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":75,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0357096","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}